What is Inozyme Pharma Earnings Yield (Joel Greenblatt) %?
Inozyme Pharma's Enterprise Value for the quarter that ended in Sep. 2024 was $250.84 Mil.
Inozyme Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-91.08 Mil. Inozyme Pharma's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2024 was -36.36%.
The historical rank and industry rank for Inozyme Pharma's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
INZY'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -895189.39 Med: 0 Max: 770189.9
Current: -85.47
During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Inozyme Pharma was 770189.90%. The lowest was -895189.39%. And the median was 0.00%.
INZY's Earnings Yield (Joel Greenblatt) % is ranked worse than 84.35% of 1367
companies
in the Biotechnology industry
Industry Median: -13.74
vs INZY: -85.47
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Inozyme Pharma's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Inozyme Pharma Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Inozyme Pharma's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inozyme Pharma's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Inozyme Pharma's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inozyme Pharma's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Inozyme Pharma's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Inozyme Pharmas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Inozyme Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-91.08 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Inozyme Pharma Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Inozyme Pharma's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INZY has been successfully added to your 